Post #41 Update on the 2014-15 Flu Vaccine

The main circulating flu this year is a recently mutated H3N2 strain (91% in one sample).  Because of this new mutation, the vaccine currently used is not a great match for this particular strain. In my medical opinion, this paradoxically makes it even MORE IMPORTANT to get the flu vaccine. Mainly, because the worse protection the flu vaccine offers, the more widespread the flu will be this year, and this increases the likelihood that a large percentage of people, both immunized and unimmunized, will contract the flu. However, those who are unimmunized will be at an even greater risk of catching the flu. Essentially, there is less herd protection this year and everyone is going to get exposed. And while the flu vaccine is not a great match it still offers some protection against the new H3N2 strain, and since it is highly likely that almost everyone is going to get exposed to the flu, some protection is better than no protection. Also, the flu vaccine protects against the 9% of other strains circulating. Sadly, 5 kids have already died this year from flu-related illnesses and the flu season is just beginning.Deadlier Flu Season Is Possible, C.D.C. Says
Source: A Pediatrician's Blog - Category: Pediatrics Source Type: blogs

Related Links:

This study aims to evaluate short-term immunogenicity and safety of influenza A/Singapore (H3N2) vaccine in SLE.METHODS: 81 consecutive SLE patients and 81 age- and sex-matched healthy controls (HC) were vaccinated with the influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus. Seroprotection (SP) and seroconversion (SC) rates, geometric mean titers(GMT), and factor increase in GMT(FI-GMT) and adverse events were assessed before and 4 weeks post-vaccination. Disease activity and therapies were also evaluated.RESULTS: Before immunization, SLE and HC groups had high SP rates (89% vs 77%, p = 0.061) and elevated GMT tite...
Source: Lupus - Category: Rheumatology Authors: Source Type: research
by Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Lakkhana Wongsrisang, Sirapa Klinfueng, Sumeth Korkong, Thanunrat Thongmee, Nasamon Wanlapakorn, Yong Poovorawan Assessing the seroprevalence of the high-risk individuals against the influenza virus is essential to evaluate the progress of vaccine implementation programs and establish influenza virus interventions. Herein, we identified the pre-existing cross-protection of the circulating seasonal influenza viruses among the older-aged population. A cross-sectional study was performed base on the 176 residual sera samples collected from older adults aged 60 to 95 years ...
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research
This report updates the 2020-21 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2020;69[No. RR-8]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. ACIP makes no preferential recommendation for a specific vaccine when more than one licensed, recommended, and age-appropriate vaccine is available. During the 2021-22 influenza season, the following types of vaccines ar...
Source: MMWR Recomm Rep - Category: Epidemiology Authors: Source Type: research
aghavan Varadarajan In current seasonal influenza vaccines, neutralizing antibody titers directed against the hemagglutinin surface protein are the primary correlate of protection. These vaccines are, therefore, quantitated in terms of their hemagglutinin content. Adding other influenza surface proteins, such as neuraminidase and M2e, to current quadrivalent influenza vaccines would likely enhance vaccine efficacy. However, this would come with increased manufacturing complexity and cost. To address this issue, as a proof of principle, we have designed genetic fusions of hemagglutinin ectodomains from H3 and H1 influen...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Vaccine. 2021 Aug 12:S0264-410X(21)01041-0. doi: 10.1016/j.vaccine.2021.08.021. Online ahead of print.ABSTRACTVaccination is the most effective approach to reduce the substantial morbidity and mortality caused by influenza infection. Vaccine efficacy is highly sensitive to antigenic changes causing differences between circulating and vaccine viruses. Adjuvants such as MF59 increase antibody-mediated cross-reactive immunity and therefore may provide broader seasonal protection. A recent clinical trial showed that an MF59-adjuvanted vaccine was more efficacious than a nonadjuvanted comparator in subjects
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
ConclusionAcute arm eccentric exercise did not influence antibody titers or cell mediated immune responses to the influenza vaccine delivered post-exercise in older adults. More strenuous exercise may be required for exercise to act as an adjuvant. ClinicalTrials.gov Identifier: NCT03736759.
Source: Frontiers in Physiology - Category: Physiology Source Type: research
This study examined the role that pre-existing immunity plays on influenza virus vaccination. Ferrets were infected with historical A(H3N2) influenza viruses isolated from either the 1970’s, 1980’s, or 1990’s and then vaccinated with computationally optimized broadly reactive antigens (COBRA) or wild-type (WT) influenza virus like particles (VLPs) expressing hemagglutinin (HA) vaccine antigens to examine the expansion of immune breadth. Vaccines with the H3 COBRA HA antigens had more cross-reactive antibodies following a single vaccination in all three pre-immune regimens than vaccines with WT H3 HA antig...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study, we produced neuraminidase type 2 (NA2) VLPs derived from the sequence of the seasonal IAV A/Perth/16/2009. Intramuscular vaccination of mice with NA2 VLPs induced high anti-NA serum IgG levels capable of inhibiting NA activity. NA2 VLP vaccination protected against mortality in a lethal A/Hong Kong/1/1968 (H3N2) virus challenge model, but not against lethal challenge with A/California/04/2009 (H1N1) virus. However, bivalent vaccination with NA1 and NA2 VLPs demonstrated no antigenic competition in anti-NA IgG responses and protected against lethal challenge with H1N1 and H3N2 viruses. Here we demonstrate tha...
Source: Virology - Category: Virology Authors: Source Type: research
More News: Blogging | Children | Contracts | H3N2 | Pediatricians | Pediatrics | Vaccines